Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fuji
Cerilliant
Mallinckrodt
Express Scripts
Covington
Moodys
QuintilesIMS
Queensland Health
Chinese Patent Office

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,546,929

« Back to Dashboard

Which drugs does patent 6,546,929 protect, and when does it expire?

Patent 6,546,929 protects EXUBERA and is included in one NDA.

This patent has one hundred and one patent family members in fifty-four countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 6,546,929
Title: Dry powder dispersing apparatus and methods for their use
Abstract:The invention provides various apparatus and methods for aerosolizing a powdered medicament. In one exemplary embodiment, an apparatus includes a pressurization cylinder, and a piston which is slidable within the cylinder to pressurize a gas. A handle is coupled to the piston and is movable between an extended position and a home position to pressurize the gas. An aerosolizing mechanism is included and is configured to aerosolize a powdered medicament that is held within a receptacle with pressurized gas from the cylinder. A carriage assembly is included to receive the receptacle and to couple the receptacle to the aerosolizing mechanism. A first and a second interlock are operably engageable with the carriage assembly to prevent coupling of the receptacle with the aerosolization mechanism. The first interlock is released to allow movement of the carriage upon movement of the handle to the extended position. The second interlock remains engaged if the receptacle is only partially inserted into the carriage assembly.
Inventor(s): Burr; John D. (Redwood City, CA), Smith; Adrian E. (Belmont, CA), Hall; Randy K. (Mountain View, CA), Snyder; Herman (Belmont, CA), Schuler; Carlos (Cupertino, CA), Axford; George S. (San Mateo, CA), Ray; Charles (Foster City, CA)
Assignee: Inhale Therapeutic Systems, Inc. (San Carlos, CA)
Application Number:09/873,946
Patent Claim Types:
see list of patent claims
Use; Device; Delivery;

Drugs Protected by US Patent 6,546,929

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-001 Jan 27, 2006 DISCN No No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTERING INSULIN VIA INHALATION ➤ Subscribe
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006 DISCN No No ➤ Subscribe ➤ Subscribe METHOD OF ADMINISTERING INSULIN VIA INHALATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,546,929

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,921,825 Adenosine A3 receptor modulators ➤ Subscribe
6,257,233 Dry powder dispersing apparatus and methods for their use ➤ Subscribe
7,470,698 Adenosine A3 receptor modulators ➤ Subscribe
6,407,236 Adenosine A3 receptor modulators ➤ Subscribe
7,271,171 Adenosine A.sub.3 receptor modulators ➤ Subscribe
6,901,929 Dry powder dispersing apparatus and methods for their use ➤ Subscribe
6,448,253 Adenosine A3 receptor modulators ➤ Subscribe
7,422,013 Dry powder dispersing apparatus and methods for their use ➤ Subscribe
8,161,969 Dry powder dispersing apparatus and methods for their use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,546,929

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1443 ➤ Subscribe
Argentina 018443 ➤ Subscribe
Austria 339232 ➤ Subscribe
Austria 414240 ➤ Subscribe
Austria 503591 ➤ Subscribe
Austria A904399 ➤ Subscribe
Australia 2002305386 ➤ Subscribe
Australia 4090599 ➤ Subscribe
Australia 6248299 ➤ Subscribe
Australia 749211 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Dow
Novartis
Daiichi Sankyo
Julphar
Baxter
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot